The importance of these mAbs in cancer immunotherapy is well known, and MM cells and their microenvironment seem to rely on the PD-1/PD-L1 interaction, thus fostering the design of clinical studies with immune checkpoint inhibitors in MM. This evidence concerns the gene PDCD1 and Miyoshi myopathy.